Reeves AA, Fuentes AV, Caballero J, et al. - Among patients treated with rilpivirine, dolutegravir and dolutegravir/rilpivirine, researchers evaluated the risk of neuropsychiatric adverse effects (ie, depression, anxiety, insomnia, dizziness, suicidal behavior) in this meta-analysis. Using Jadad scoring system, the quality of evidence was assessed. The sample consisted of adult participants (18 years of age or older) receiving dolutegravir 50 mg, rilpivirine 25 mg or a combination of dolutegravir 50 mg/rilpivirine 25 mg once daily. They included twenty studies (n = 10,998) with a minimum period of 48 weeks and an average Jadad score of 4. The use of dolutegravir and rilpivirine together tends to increase the risk of developing depressive symptoms. Despite the increase, the clinical significance is uncertain, and further research is required. Furthermore, compared to efavirenz-based antiretroviral therapy, the risk of neurotoxicity seems comparable to that seen with dolutegravir, rilpivirine, and dolutegravir/rilpivirine antiretroviral therapy.